TCT-624 Clinical Outcomes with Everolimus-Eluting Stent for the Treatment of Cardiac Allograft Vasculopathy  by Azarbal, Babak et al.
Lesion Characteristics at the Time of the Initial DES Implantation
Procedure
ST Group Lesion
n382
Control Group
Lesion n421 p value
Left Main Lesion 0% 0.7% 0.251
LAD Lesion 40.3% 34.7% 0.099
LCX Lesion 18.1% 25.4% 0.012
RCA Lesion 37.4% 37.5% 0.978
Bypass Graft
Lesion
4.2% 1.7% 0.032
Type C Lesion 80.4% 85.5% 0.052
Pre TIMI Flow 0 18.6% 10.9% 0.002
Thrombus 39.9% 28.9% 0.001
Lesion Length mm 19.53 	/ 12.01 16.84 	/ 10.02 0.001
Reference Vessel
Diameter mm
2.76 	/ 0.43 2.71 	/ 0.45 0.123
Pre MLD mm 0.67 	/ 0.47 0.75 	/ 0.46 0.018
Pre Diameter
Stenosis %
75.90 	/ 16.50 72.61 	/ 15.82 0.004
Final In Stent MLD
mm
2.56 	/ 0.41 2.60 	/ 0.46 0.201
Final In Segment
MLD mm
2.27 	/ 0.42 2.26 	/ 0.45 0.866
Final In Segment
Acute Gain
1.60 	/ 0.53 1.52 	/ 0.55 0.027
Final In Stent
Diameter
Stenosis %
8.98 	/ 8.96 6.06 	/ 9.22 0.001
Final Stented
Length mm
28.23 	/ 15.69 22.80 	/ 12.46 0.001
Final TIMI Flow III 96.1% 97.4% 0.305
Abrupt Closure/No
Reflow
0% 0% --
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Angiographic Outcomes in “One-Stop” Hybrid Coronary Revascularization
vs. Percutaneous Coronary Intervention for the Treatment of Multivessel
Coronary Artery Disease: A Propensity Score Matching Analysis
Yi Shi1, Shengshou Hu1, Zhe Zheng1, Bo Xu1, Wei Wang1, Ran Xia1,
Run-Lin Gao1
1Fu Wai Hospital, National Center for Cardiovascular Diseases, China, Beijing,
China
Background: “One-stop” hybrid coronary revascularization (HYBRID) with LIMA-
LAD bypass grafting and DES implantations in non-LAD lesions is a newer therapy for
the treatment of multivessel coronary artery disease. The present study aimed to compare
the angiographic patency rates between HYBRID and PCI at mid-term repeat coronary
angiogram.
Methods: From June 2007 to December 2009, 104 patients underwent HYBRID and
7165 patients underwent PCI with DES implantations at our center. The major inclusion
criteria of the study are: 1) triple vessel disease including revascularizable LAD lesion; 2)
heart team consensus reached that either HYBRID or PCI could be performed in each
individual; 3) no chest pain and MACCE occurred during clinical follow-up. According
to these, 102 patients in Hybrid group and 157 patients in PCI group who agrees to take
repeat angiogram were enrolled. From October, 2010 to December, 2011, 50 HYBRID
patients signed the agreement and underwent angiogram. Among the 157 PCI cases, 50
patients (1:1) are selected for repeat angiography with the use of propensity score
matching method.
Results: The angiographic follow-up durations were similar the two groups (18  8.03
months vs. 19.3  9.12 months). There are no significant differences in baseline
characteristics. There were 50 LIMA grafts and 64 non-LAD target vessels in Hybrid
group; the angiographic target vessel patency rate was 89.5%, and the TLR rate was 7.9%.
In PCI group, the angiographic target vessel patency rate was 82.7%, and the TLR rate
was 20.4%. There was no significant difference in overall patency between the Hybrid
group and PCI group (89.5% vs. 82.7%, p0.07), but a significantly higher patency rate
of LIMA-LAD graft in Hybrid group vs. that of stented LAD in PCI group (98% vs. 80%,
p0.004); and no significant difference in non-LAD target vessel patency between the
two groups (82.8% vs. 85.2%, p0.727).
Conclusions: Compared to PCI with DES implantations, the treatment of multivessel
coronary artery disease with “one-stop” hybrid revascularization demonstrated that the
patency rate of LIMA-LAD graft was superior to that of PCI in LAD, and the non-LAD
vessel patency rate was similar in two groups.
TCT-623
Efficacy of Additional Ballooning with a Dual Wire Balloon After Rotational
Atherectomy to Expand the Drug-Eluting Stent for Heavily Calcified
Coronary Lesions
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Yasuhiro Satoh1
1Disaster Medical Center, Tokyo, Japan, 2Tahara Hohoemi Clinic, Tokyo, Japan
Background: Calcified lesions have been known as a cause of stent underexpansion
which increases the risk of thrombosis and in-stent restenosis. We evaluated a combina-
tion therapy using a dual wire balloon with integral nitinol wire after RA for heavily
calcified lesions.
Methods: 64 consecutive heavily calcified lesions which need rotational atherectomy
(RA) for stent implantation were evaluated. 18 lesions without intravascular ultrasound
(IVUS) results and 6 lesions with chronic total occlusion were excluded. 22 lesions treated
with a combination therapy using a dual wire balloon after RA. The other 18 lesions were
treated with RA alone or the combination therapy using the conventional semi-compliant
balloon and RA. After RA, the drug eluting stent (DES) was implanted in all cases. Just
after RA, the section with smallest luminal cross sectional area (CSA) with an angle of
more than 180 degree calcification was identified by IVUS and the following measure-
ments made at the lesion. Angiographic findings were evaluated just after treatment and
11 months after treatment.
Results: Baseline patient’s characteristics, lesion characteristics calculated by quantita-
tive coronary angiography, therapeutic procedures were not different between 2 groups.
Before implantation of DES, a dual wire balloon enabled adequate dilatation with
significantly more cracks without major complications. The minimal stent CSA and the
stent expansion ratio which calculated the measured minimal stent CSA divided by the
minimal stent CSA predicted by the compliance chart, were similar in both groups.
However, the symmetrical expansion was significantly accomplished in the dual wire
group compared to the other group (mean ratio calculated by dividing the shortest
diameter by the longest diameter at the site of the minimal stent CSA was 0.810.06 vs.
0.770.06, P0.02). Moreover, the angiographic restenosis rate (6.25% vs. 18.2%,
P0.55) and the target vessel revascularization rate (0% vs. 9.1%, P0.39) at 11 months
after treatment were not significantly different in both groups.
Conclusions: By using a dual wire balloon after RA, the adequate symmetrical stent
expansion and the acceptable mid-term outcomes were accomplished.
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Cardiac Allograft Vasculopathy
Babak Azarbal1, Boris Arbit2, Radhakrishnan Ramaraj2, David Chang1,
Jignesh Patel1, Jon Kobashigawa1
1Cedars-Sinai Heart Institute, Beverly Hills, CA, 2Cedars-Sinai Medical Center,
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Background: Transplant coronary artery disease (TCAD) is a major cause of mortality
in patients who are status post orthotopic heart transplantation (OHT). Use of systemic
everolimus in OHT patients has been shown to reduce the incidence of TCAD. The safety
and efficacy of Xience V, a second-generation everolimus-eluting stent (EES), has not
been previously studied in OHT patients.
Methods: Patients with OHT who had hemodynamically significant CAD (left main
50%, or angiographic diameter stenosis 70%), and underwent percutaneous coronary
intervention (PCI) with EES were included in the study. We examined procedural success
rates, in-hospital and one year mortality and myocardial infarction rates. Primary outcome
was target lesion revascularization (TLR). Follow up angiograms were performed at 1
year. Quantitative coronary analysis was used for stenosis analysis.
Results: PCI was performed in 24 lesions, and 26 denovo EES were placed. One stent
was placed into the left main artery, 12 in left anterior descending, 7 in right coronary
artery, and 4 in the left circumflex. The average stent length was 15 4.9mm and the
average stent diameter was 3  0.6mm. Procedural success rate was 100%. All patients
had angiographic follow-up (325  128 days). There were no periprocedural, 30-day, or
1 year deaths/ MIs. No stent thrombosis was noted; 1 patient had focal in-stent restenosis.
Target vessel revascularization (TVR) rate was 4.1% (1/24), and TLR rate was 3.8%
(1/26).
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Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Left circumflex artery 4
Number of patients 13
Angiographic success rate 100%
MI/Cardiac death in-hospital, 1 yr 0
Stent diameter (mm) 3 0.6
Stent length (mm) 15 4.9
Number of lesions treated 24
Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Number of stents 26
Angiographic follow-up 100%
Length of follow-up 325 128
Binary restenosis 7.4%
Target vessel revascularization 1/24 (4.1%)
Target lesion revascularization 1/26 (3.8%)
Conclusions: EES is associated with a very low incidence of instent stenosis and target
lesion revascularization in patients with TCAD. Further studies are needed to determine
whether PCI with EES could alter the long term outcome of patients with TCAD.
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THREE YEAR FOLLOW UP OF A RANDOMIZED COMPARISON OF
NOBORI, BIOLIMUS A9 ELUTING STENT(BES) WITH CYPHER,
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REVASCULARIZATION IN JAPANESE POPULATION
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Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting
Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-
proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori
stent comparing to Cypher stent in Japanese population by a single blinded 3:2
randomized trial and met the primary endpoint, non inferiority in TVF. This is the first
report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to
Cypher Sirolimus Eluting stent in Japanese population.
Methods: This is the first multicenter single-blinded, 3:2 randomized clinical trial
comparing Nobori and Cypher in 335 patients (Nobori 198 : Cypher 137) in Japan.
Patients with single de novo up to two native coronary lesions were treated. The primary
endpoint was TVF (cardiac death, MI and TVR) rate at 9 months; late loss (LL) and
restenosis rate (RR) at 8 months were major secondary angiographic endpoints, while
MACE and stent thrombosis were major secondary safety endpoints. Duration of dual
antiplatelet therapy (DAPT) was also recorded for all patients.
Results: No significant difference between both patient backgrounds was found. TLR
free rate of Nobori was 98.8% at 2years and 98.3% at 3years. (Cypher 96.0% and 95.2%).
MACE free rate of Nobori was 94.1% at 2years and 92.9% at 3years. (Cypher 93.7% and
92.0%). TVF free rate of Nobori was 92.1% at 2years and 90.9% at 3years. (Cypher
93.7% and 91.1%). No definite or probable stent thrombosis according to ARC definition
were found in both groups.
Conclusions: In this first randomized clinical trial of Nobori and Cypher stent in
Japanese population, Nobori stent was found non-inferior to Cypher in TVF, the primary
endpoint. TLR free rate at 3 years of Nobori tended to be higher than that of Cypher and
the differences in TLR free rate between Nobori and Cypher at 2 years and 3years were
increased (no statistical significance). MACE and TVF free rate of both stents at three
years were comparable. Further long term follow-up up to 5years may suggest longer term
safety of Nobori Stent.
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Background: There are few studies comparing the long-term clinical outcomes of
patients (pts) with peri-procedural myocardial infarction (P-MI) with those without P-MI
following percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in
real world clinical practice.
Methods: A total of 1119 pts underwent PCI with DESs between 2004 and 2010 were
enrolled (control group, n1006 pts and P-MI group, n113 pts). P-MI was defined as
major CK-MB elevation (3X the upper limit of normal [ULN]) after PCI.
Results: There were no significant differences between the two groups except P-MI
group was more elderly, had more female, longer procedure time, higher number of target
vessel and stents. At 6 month routine follow-up angiography, there was no significant
difference in mean diameter stenosis %, incidence of binary restenosis and late loss
between the two groups. Among the major in-hospital outcomes, cardiac death was higher
in P-MI group. At 2-year (follow-up, 89.1%), and the cumulative incidence of total death,
cardiac death and total major adverse cardiac events (MACEs) were higher in P-MI group,
where as repeat PCI including target lesion revascularization (TLR) and target vessel
revascularization (TVR). However, when in-hospital mortality was excluded, the major
clinical outcomes were not different between the two groups up to 2 years (table).
Conclusions: P-MI was mainly associated with in-hospital cardiac death following PCI
with DES in real world clinical practice. However, P-MI doesn’t seem to be an
independent predictor for adverse clinical outcomes for long-term period.
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Does direct DES stenting reduces restenosis; a randomized comparison of
direct stent implantation to stenting with predilation or provisional stenting in
elective PCI patients
Samer Somi1, Wouter Remkes1, Jan-Henk Dambrink1, Marcel Gosselink1,
Jan Hoorntje1, Harry Suryapranata1, Jan Paul Ottervanger1, Arnoud van ’t Hof1
1Isala Klinieken, Zwolle, Netherlands
Background: Previous studies were performed to investigate whether a strategy of direct
stent implantation without pre-dilatation is associated with a reduced incidence of
restenosis, compared to conventional stenting with pre-dilatation. However, none of these
studies were performed in the drug-eluting stent era. Therefore the STRESSED (direct
Stenting To Reduce REStenosis in Stent Era with Drug elution) study was designed and
carried out.
Methods: A total of 600 patients with stable or unstable angina pectoris or a recent (30
days) myocardial infarction were randomized to direct stenting, stenting after pre-
dilatation or a provisional stenting strategy. Primary endpoint was the mean minimal
lumen diameter (MLD) at 9 months follow-up angiography. Secondary endpoints were
the clinical procedural success defined as angiographic success without major adverse
cardiac events (MACE) at 9 months and two years follow-up.
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